BMS-986298-01

DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies.

LAG-3 is a key immune checkpoint molecule found on immune cells that can inhibit T cell function and allow tumors to evade immune system attack.

Akeso's gumokimab, an IL-17 targeting monoclonal antibody, has its NDA accepted by China's NMPA for treating moderate to severe plaque psoriasis.

The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for subcutaneous use, offering a new administration option for various solid tumors.

The FDA approved Opdivo Qvantig, a subcutaneous injection of nivolumab, for adult solid tumors previously approved for intravenous Opdivo.